Pfizer completed a $54 billion acquisition of CGen, a leader in cancer-fighting technologies, as part of a strategic shift toward oncology. Critics of the pharmaceutical giant have linked this move to the rise of "turbo cancers" and the company's need for new revenue streams following the decline of COVID-19 vaccine sales.
